Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2020

View Archived Issues

Bayer begins phase II study of inhaled PEGylated adrenomedullin in ARDS

Statins present antifungal and antibiofilm potential against S. schenckii complex species in vitro

Localized bile acid improves systemic blood glucose control

"The joints are elsewhere": for neurodegeneration, a different way to slice the pie

Araim Pharmaceuticals reports phase II data for cibinetide in DME

Discovery of SHS-4121705 as a novel mitochondrial uncoupler for the treatment of NASH

FDA clears IND to expand phase II study of favipiravir for the prevention of COVID-19

Positive topline data from phase Ib study of AG-019

Nuvation Bio identifies new adenosine A2A receptor antagonists

New protein kinase inhibitors discovered at Voronoi

First patient dosed in clinical trial of Allocetra in severe COVID-19

Abbisko Therapeutics discloses Nuclear receptor RORgammaT agonists

New RIP-1 kinase 1 inhibitors synthesized at Beijing Scitech-Mq Pharmaceuticals

HitGen patents STING agonists

AnaptysBio reports interim analysis data from ECLIPSE phase II study of etokimab

FDA gives may proceed notice for phase IIb/III study of SLS-005 in ALS

IDMC recommends continuation of phase IIb trial of XF-73 for postsurgical bacterial infections

Positive interim data presented from EQUATE study of itolizumab in acute GvHD

Phase III data show ensartinib significantly prolongs PFS over crizotinib in ALK-positive NSCLC

Phase IIa study of KY-1005 in atopic dermatitis meets primary endpoints

New triple-modal nanoparticle therapy overcomes drug resistance in bladder cancer models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...